The Latest Breaking News from Eli Lilly

The stock market was up and down with Trump tariff fears in focus. Palantir led big earnings winners. Google and Amazon were losers.

As Eli Lilly has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

March S&P 500 E-Mini futures (ESH25) are up +0.20%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.10% this morning, suggesting Wall Street is set to extend yesterday’s gains, while investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from…

March S&P 500 E-Mini futures (ESH25) are up +0.05%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from “Magnificent Seven” member Amazon.

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance. Will it continue?

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

This weight-loss underdog doubled in a single day last week and could deliver even bigger rewards.